Zepbound (tirzepatide): the 2026 buyer's guide
Zepbound is Eli Lilly's once-weekly tirzepatide injection, approved by the FDA in 2023 for chronic weight management. Tirzepatide is the only dual GLP-1/GIP receptor agonist approved for obesity. Below: how it works, trial efficacy, 2026 pricing and which programs prescribe it.
Compare Zepbound prices →- Zepbound is a weekly injection of tirzepatide, FDA-approved for chronic weight management since 2023.
- In the SURMOUNT-1 trial, mean weight loss was 20.9% over 72 weeks, with 56.7% of patients losing 15% or more of body weight.
- It carries the GLP-1 class boxed warning for thyroid C-cell tumor risk, and is not for people with a personal or family history of medullary thyroid carcinoma or MEN2.
- Cash, insurance and compounded prices differ widely. See the cost breakdown below, and the all-in program costs on the chart.
What Zepbound costs in 2026
There is no one price. What you pay depends on which path you take:
Telehealth programs add a membership fee on top of the medication cost (typically $40-$200/mo). For all-in monthly costs by program, see the chart, the full GLP-1 cost guide, or calculate your exact all-in cost by drug, coverage and state.
For every cash path to Zepbound without insurance, the $299 to $449 LillyDirect vials, the $1,099 retail list price and the $278 compounded tirzepatide route, see the Zepbound cost guide.
Who it's for
Adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Also approved for obstructive sleep apnea in adults with obesity (2024).
What the trials show
Zepbound's registration trial was SURMOUNT-1 (NEJM, 2022). At 72 weeks at the maximum dose, mean weight loss was 20.9% (17.8 percentage points greater than placebo). 91% of patients lost at least 5% of body weight; 56.7% lost at least 15%. Real-world results vary; trial patients are typically more adherent and more closely managed than typical telehealth patients.
Dose schedule
Dose levels: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg. Standard practice is to titrate up monthly, holding at any tolerated dose. Maximum dose is 15mg weekly; many patients reach goal weight at sub-maximum doses and stay there.
Common side effects
The most commonly reported side effects in the registration trial:
- nausea (29%)
- diarrhea (23%)
- constipation (17%)
- vomiting (13%)
- abdominal pain (10%)
Boxed warning: Risk of thyroid C-cell tumors (rodent data); contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
How Zepbound differs from related drugs
Same molecule as Mounjaro, branded specifically for weight loss. The dual-agonist mechanism produces greater mean weight loss in trials than semaglutide-only drugs.
Compounded tirzepatide
Compounded tirzepatide is the same active molecule prepared by a 503A pharmacy under prescription rather than manufactured under FDA new-drug approval as Zepbound. Cash-pay savings versus branded Zepbound are typically 50-80%. The regulatory environment has tightened. Briefly on FDA shortage list early 2024, off the list since late 2024. Lilly has filed coordinated lawsuits against compounded tirzepatide pharmacies through 2025-2026. For the comparison, see compounded tirzepatide vs Zepbound.
Programs that prescribe Zepbound
These programs in our chart prescribe Zepbound (with insurance coverage where applicable, or as a cash-pay option). Ranked by overall score.
Some visit links earn us a commission.
Zepbound vs other GLP-1s
Clinical indications
Beyond obesity, Zepbound carries two additional FDA-approved indications. For moderate-to-severe sleep apnea (after SURMOUNT-OSA), see the OSA and GLP-1 guide. For HFpEF with obesity (heart failure with preserved ejection fraction), see the HFpEF and GLP-1 guide.
Learn more about Zepbound
References
- SURMOUNT-1 registration trial. New England Journal of Medicine, 2022.
- Zepbound FDA prescribing information (DailyMed).
Trial figures are mean results at the maximum dose in the cited registration trial. Real-world outcomes vary with adherence and clinical management.
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe or fulfill medications. Talk to a licensed clinician about whether Zepbound is appropriate for you. Pricing reflects publicly verified rates as of June 22; verify with the manufacturer or your prescriber before committing.
